TTC17 deficiency was correlated with more aggressive clinicopathologic characteristics in BC patients and sensitized BC to rapamycin and paclitaxel, thereby acting as a robust predictive and prognostic biomarker for BC. This evidence concerns the gene TTC17 and breast cancer.